Bellerophon Therapeutics Stock Current Asset
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
Bellerophon Therapeutics fundamentals help investors to digest information that contributes to Bellerophon Therapeutics' financial success or failures. It also enables traders to predict the movement of Bellerophon Pink Sheet. The fundamental analysis module provides a way to measure Bellerophon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellerophon Therapeutics pink sheet.
Bellerophon |
Bellerophon Therapeutics Company Current Asset Analysis
Bellerophon Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Bellerophon Therapeutics Current Asset | 29.45 M |
Most of Bellerophon Therapeutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellerophon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Bellerophon Therapeutics has a Current Asset of 29.45 M. This is 98.63% lower than that of the Health Care Equipment & Supplies sector and 97.22% lower than that of the Health Care industry. The current asset for all United States stocks is 99.68% higher than that of the company.
Bellerophon Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellerophon Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellerophon Therapeutics could also be used in its relative valuation, which is a method of valuing Bellerophon Therapeutics by comparing valuation metrics of similar companies.Bellerophon Therapeutics is currently under evaluation in current asset category among its peers.
Bellerophon Fundamentals
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.6 | ||||
| Profit Margin | (2.20) % | ||||
| Operating Margin | (2.48) % | ||||
| Current Valuation | (9.32 M) | ||||
| Shares Outstanding | 12.23 M | ||||
| Shares Owned By Insiders | 3.97 % | ||||
| Shares Owned By Institutions | 45.08 % | ||||
| Number Of Shares Shorted | 90.45 K | ||||
| Price To Earning | 5.33 X | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (22.39 M) | ||||
| Net Income | (19.83 M) | ||||
| Cash And Equivalents | 16.33 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 203 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.12 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (17.77 M) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 1.25 M | ||||
| Total Asset | 7.93 M | ||||
| Retained Earnings | (252.08 M) | ||||
| Working Capital | 2.16 M | ||||
| Current Asset | 29.45 M | ||||
| Current Liabilities | 8.07 M | ||||
| Z Score | -49.75 | ||||
| Net Asset | 7.93 M |
About Bellerophon Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellerophon Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellerophon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellerophon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |